<DOC>
	<DOCNO>NCT00077116</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy , idarubicin cytarabine , work different way stop cancer cell divide stop grow die . Monoclonal antibody , gemtuzumab ozogamicin , locate cancer cell either kill deliver cancer-killing substance without harm normal cell . Giving monoclonal antibody therapy together chemotherapy may kill cancer cell . Giving healthy stem cell donor whose blood closely resemble patient 's blood help patient 's bone marrow make new stem cell become red blood cell , white blood cell , platelet . PURPOSE : This phase II trial study well give idarubicin cytarabine together gemtuzumab ozogamicin work treat patient previously untreated high-risk myelodysplastic syndrome acute myeloid leukemia secondary myelodysplastic syndrome .</brief_summary>
	<brief_title>Idarubicin , Cytarabine , Gemtuzumab Ozogamicin Treating Patients With Previously Untreated High-Risk Myelodysplastic Syndrome Acute Myeloid Leukemia Secondary Myelodysplastic Syndrome</brief_title>
	<detailed_description>OBJECTIVES : Primary - Determine feasibility combine gemtuzumab ozogamicin idarubicin cytarabine without cyclophosphamide total body irradiation v busulfan follow allogeneic stem cell transplantation patient previously untreated high-risk myelodysplastic syndrome ( MDS ) acute myeloid leukemia secondary MDS . - Determine toxicity profile regimen patient . - Determine antileukemic/anti-MDS activity regimen patient . Secondary - Determine hepatotoxicity regimen , term veno-occlusive disease , patient . - Determine severity pancytopenia duration recovery patient treat regimen . OUTLINE : This multicenter study . Patients assign 1 2 treatment group . - Group 1 ( patient HLA-matched sibling donor ) : Patients receive remission-induction chemotherapy comprise idarubicin IV 5 minute day 1 , 3 , 5 ; cytarabine IV continuously 24 hour day 1-10 ; gemtuzumab ozogamicin IV 2 hour day 7 . Treatment continue second course absence unacceptable toxicity . - Group 2 ( patient HLA-matched sibling donor ) : Patients randomize 1 2 treatment arm . - Arm I : Patients receive myeloablative consolidation chemotherapy comprise cyclophosphamide day -6 -5 total body irradiation twice daily day -4 -2 . - Arm II : Patients receive myeloablative consolidation chemotherapy comprise busulfan day -8 -5 cyclophosphamide day -4 -3 . Patients arm may alternatively undergo T-cell depletion and/or reduced-intensity conditioning regimen . Approximately 4-8 week completion consolidation chemotherapy , patient group 2 undergo allogeneic bone marrow transplantation allogeneic peripheral blood stem cell transplantation . Patients group 2 proceed remission-induction chemotherapy group 1 . Patients achieve complete remission recommend consolidation therapy study . Patients follow monthly 6 month , every 2 month 6 month , every 3 month thereafter . PROJECTED ACCRUAL : A total 28 patient accrue study within 10 month .</detailed_description>
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Myeloid</mesh_term>
	<mesh_term>Leukemia , Myeloid , Acute</mesh_term>
	<mesh_term>Myelodysplastic Syndromes</mesh_term>
	<mesh_term>Preleukemia</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Cytarabine</mesh_term>
	<mesh_term>Busulfan</mesh_term>
	<mesh_term>Gemtuzumab</mesh_term>
	<mesh_term>Idarubicin</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm diagnosis 1 following : Highrisk myelodysplastic syndrome ( MDS ) , include follow : Refractory anemia excess blast ( RAEB ) &gt; 10 % blast cell bone marrow RAEB transformation Other form MDS multiple ( 3 ) chromosomal abnormality chromosome 7 abnormality AND/OR profound cytopenia , define neutrophil count &lt; 500/mm^3 and/or platelet count &lt; 20,000/mm^3 Chronic myelomonocytic leukemia &gt; 5 % blast cell bone marrow Chronic myelomonocytic leukemia neutrophil count &gt; 16,000/mm^3 OR monocyte count &gt; 2,600/mm^3 Secondary acute myeloid leukemia supervene overt MDS 6 month duration Patients without HLAidentical sibling No active CNS leukemia PATIENT CHARACTERISTICS : Age 16 70 Performance status WHO 02 Life expectancy Not specify Hematopoietic See Disease Characteristics Hepatic Bilirubin ≤ 1.5 time upper limit normal ( ULN ) Renal Creatinine ≤ 1.5 time ULN Cardiovascular No severe cardiovascular disease No arrhythmia require chronic treatment No congestive heart failure No symptomatic ischemic heart disease Pulmonary No severe lung disease Other Not pregnant nursing Fertile patient must use effective contraception No HIV positivity No concurrent malignant disease No active uncontrolled infection No history alcohol abuse ( i.e. , average less 5 alcoholic consumption daily past year ) No concurrent severe neurological psychiatric disease No psychological , familial , sociological , geographical condition would preclude study compliance PRIOR CONCURRENT THERAPY : Biologic therapy More 6 week since prior growth factor Chemotherapy No prior intensive chemotherapy More 6 week since prior lowdose chemotherapy hydroxyurea Endocrine therapy Not specify Radiotherapy Not specify Surgery Not specify Other More 6 week since prior immunosuppressant No prior participation clinical study</criteria>
	<gender>All</gender>
	<minimum_age>16 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>July 2012</verification_date>
	<keyword>untreated adult acute myeloid leukemia</keyword>
	<keyword>refractory anemia excess blast</keyword>
	<keyword>refractory anemia excess blast transformation</keyword>
	<keyword>chronic myelomonocytic leukemia</keyword>
	<keyword>de novo myelodysplastic syndrome</keyword>
	<keyword>secondary myelodysplastic syndrome</keyword>
	<keyword>adult acute myeloid leukemia ( 8 ; 21 ) ( q22 ; q22 )</keyword>
	<keyword>adult acute myeloid leukemia ( 16 ; 16 ) ( p13 ; q22 )</keyword>
	<keyword>adult acute myeloid leukemia inv ( 16 ) ( p13 ; q22 )</keyword>
	<keyword>adult acute myeloid leukemia 11q23 ( MLL ) abnormality</keyword>
	<keyword>adult acute myeloid leukemia ( 15 ; 17 ) ( q22 ; q12 )</keyword>
	<keyword>childhood myelodysplastic syndrome</keyword>
</DOC>